Harborside


Zelira Therapeutics Limited

ZLDAF


Canadian symbol: ZLDAF
US symbol: ZLDAF

Currency in USD

Valuation Measures4

Market Cap (intraday) 8.65M
Enterprise Value 7.16M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)6.71
Price/Book (mrq)0.35
Enterprise Value/Revenue 4.65
Enterprise Value/EBITDA -0.61

Trading Information

Stock Price History

Beta (5Y Monthly) 1.76
52-Week Change 3-83.81%
S&P500 52-Week Change 3-16.88%
52 Week High 37.8754
52 Week Low 30.0850
50-Day Moving Average 31.2560
200-Day Moving Average 31.8922

Share Statistics

Avg Vol (3 month) 3722
Avg Vol (10 day) 3411
Shares Outstanding 59.58M
Implied Shares Outstanding 6N/A
Float 86.21M
% Held by Insiders 133.26%
% Held by Institutions 13.27%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:175
Last Split Date 3Apr 13, 2022

Financial Highlights

Currency in AUD.

Fiscal Year

Fiscal Year Ends Jun 29, 2022
Most Recent Quarter (mrq)Jun 29, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-857.21%

Management Effectiveness

Return on Assets (ttm)-21.42%
Return on Equity (ttm)-33.77%

Income Statement

Revenue (ttm)1.54M
Revenue Per Share (ttm)0.19
Quarterly Revenue Growth (yoy)41.90%
Gross Profit (ttm)601.57k
EBITDA -12.73M
Net Income Avi to Common (ttm)-11.95M
Diluted EPS (ttm)-1.0490
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.75M
Total Cash Per Share (mrq)0.29
Total Debt (mrq)500.91k
Total Debt/Equity (mrq)1.40
Current Ratio (mrq)3.12
Book Value Per Share (mrq)3.68

Cash Flow Statement

Operating Cash Flow (ttm)-9.43M
Levered Free Cash Flow (ttm)-5.69M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
ZLDAF
Zelira Therapeutics
1 month ago
ZLDAF
Zelira Therapeutics
2 months ago
ZLDAF
Zelira Therapeutics
2 months ago
ZLDAF
Zelira Therapeutics
6 months ago
ZLDAF
Zelira Therapeutics
7 months ago
ZLDAF
Zelira Therapeutics
8 months ago
ZLDAF
Zelira Therapeutics
10 months ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
1 year ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago
ZLDAF
Zelira Therapeutics
2 years ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
33.26%% of Shares Held by All Insider
3.27%% of Shares Held by Institutions
4.89%% of Float Held by Institutions
1Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Zelira Therapeutics Limited


Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets

Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets

Patented Tech Easily Transforms Distillate into "Free flow" Powder Matrix PHILADELPHIA, Sept. 20, 2022 -- Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is pleased to announce the launch of ZYRAYDI™, its patented, licensable ... Read More...
Zelira's Zenivol™, the World's First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany

Zelira’s Zenivol™, the World’s First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany

Zenivol™ is the world's first and only clinically validated, cannabis-based pharmaceutical sleep medication. Tweet this "The formal approval of Zenivol™ by BfArM in Germany marks a major milestone for Zelira; Germany is one of the largest global markets for cannabinoid-based medicines, and also one of the highest quality global regula... Read More...
Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary

Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary

FIVE™ line is Zelira's first step into the acne medication market valued at more than US$11 billion worldwide. Tweet this The five-product RAF FIVE™ line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, After Hours Moisturizing Lotion Acne Treatm... Read More...
Zelira Therapeutics Expands HOPE™ Distribution in the US Through Licensing Agreement with Alternative Solutions in Washington DC

Zelira Therapeutics Expands HOPE™ Distribution in the US Through Licensing Agreement with Alternative Solutions in Washington DC

Alternative Solutions will produce and distribute the HOPE™ line, Zelira's product developed for autism patients. Tweet this "Alternative Solutions is a leader in the DC medical cannabis market, and we couldn't have a better partner to launch HOPE™ in the nation's capital," says Dr. Oludare Odumosu, CEO & Managing Director USA fo... Read More...
Zelira Therapeutics Enters Agreement with Cardiovascular Solutions of Central Mississippi to Develop Products

Zelira Therapeutics Enters Agreement with Cardiovascular Solutions of Central Mississippi to Develop Products

Addressing Health Risks in Patients with Peripheral Arterial Disease and Diabetic NeuropathiesPHILADELPHIA, July 22, 2020 -- Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding agreement with US-based Cardiova... Read More...
Zelira Therapeutics Completes World's First Clinical Trials for Treatment of Insomnia with Medical Cannabis

Zelira Therapeutics Completes World’s First Clinical Trials for Treatment of Insomnia with Medical Cannabis

PHILADELPHIA, April 7, 2020 -- Zelira Therapeutics Ltd (ASX: ZLD,OTCQB: ZLDAF), a global leader in the development of clinically validated cannabis medicines based in both Perth, Australia and Philadelphia, is pleased to announce it has received the final report for its ZTL-101 medicinal cannabis trial for insomnia. Its findings represent... Read More...
Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia

Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia

Zelira Therapeutics Ltd (ASX: ZLD,OTCQB: ZLDAF), a global leader in the development of clinically validated cannabis medicines, today announced positive Phase 1b/2a results confirming that ZLT-101 therapy achieved the primary endpoint of a statistically significant improvement in Insomnia Severity Index scores in patients diagnosed with c... Read More...
Zelira Therapeutics To Collaborate With The Parkinson's Foundation

Zelira Therapeutics To Collaborate With The Parkinson’s Foundation

PERTH, Australia, Jan. 28, 2020 -- Zelira Therapeutics Limited (ASX: ZLD,OTCQB: ZLDAF) is pleased to announce a collaboration with the Parkinson's Foundation, one of the United States of America's leading communities for people living with Parkinson's disease (PD), to gather insights from people with PD about their understanding of and us... Read More...
Zelda to merge with US-based Ilera Therapeutics to create a leading global therapeutic medicinal cannabis company

Zelda to merge with US-based Ilera Therapeutics to create a leading global therapeutic medicinal cannabis company

- Merger brings together a leading pipeline of clinical candidates, revenue generating medicines, and a combined strategy to disrupt global medicinal cannabis and pharmaceutical markets- With operations in Australia and the USA, the merged company will have access to the world's largest, most profitable and fastest growing medicinal canna... Read More...
Coming Soon.

Delayed data (1h)


Share this page